Biochemistry

Carlos Fernandez-Patron

Carlos Fernandez-Patron

Ph.D, Bioanlytical Chemistry, Havana, Cuba
M.Sc., Physics, Dresden, Germany


Associate Professor
Office: 780-492-9540
Lab: 780-492-7618
Fax: 780-492-0886
carlos.fernandez-patron@ualberta.ca


Selected Publications:

 
The following 3 papers identify a novel enzyme (which we coined "cardiac sPLA2") and a mechanism whereby the heart modulates systemic inflammation and metabolism:
  1. Matrix metalloproteinase-2 negatively regulates cardiac secreted phospholipase a2 to modulate inflammation and fever.
    Berry E, Hernandez-Anzaldo S, Ghomashchi F, Lehner R, Murakami M, Gelb MH, Kassiri Z, Wang X, Fernandez-Patron C.
    J Am Heart Assoc. (2015) 4(4).


  2. Emergence of a metalloproteinase / phospholipase a2 axis of systemic inflammation.
    Fernandez-Patron C, Leung D.
    Metalloproteinases Med. (2015) 2:29-38.


  3. Identification of a novel heart/liver axis: Matrix metalloproteinases-2 negatively regulates cardiac secreted phospholipase a2 to modulate lipid metabolism and inflammation in the liver. 
    Hernandez-Anzaldo S, Berry E, Brglez V, Leung D, Yun TJ, Lee JS, Filep JG, Kassiri Z, Cheong C, Lambeau G, Lehner R, Fernandez-Patron C.
    J Am Heart Assoc. (2015) Nov 13;4(11).
 
The following 2 papers led to a new protein detection method marketed worldwide by various biotech companies:
  1. Reverse staining of sodium dodecyl sulfate polyacrylamide gels by imidazole-zinc salts: Sensitive detection of unmodified proteins.
    Fernandez-Patron C, Castellanos-Serra L, Rodriguez P.
    Biotechniques. (1992) 12:564-573.


  2. Understanding the mechanism of the zinc-ion stains of biomacromolecules in electrophoresis gels: Generalization of the reverse-staining technique.
    Fernandez-Patron C, Castellanos-Serra L, Hardy E, Guerra M, Estevez E, Mehl E, Frank RW.
    Electrophoresis. 1998;19:2398-2406.
 
The following 7 papers describe novel functions of MMPs in cardiovascular function:
  1. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. 
    Fernandez-Patron C, Radomski MW, Davidge ST.
    Circ Res. (1999)85:906-911.


  2. Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction.
    Fernandez-Patron C, Stewart KG, Zhang Y, Koivunen E, Radomski MW, Davidge ST.
    Circ Res. (2000) 87:670-676.


  3. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway.
    Hao L, Du M, Lopez-Campistrous A, Fernandez-Patron C.
    Circ Res. (2004) 94:68-76.


  4. Matrix metalloproteinase-7 and adam-12 (a disintegrin and metalloproteinase-12) define a signaling axis in agonist-induced hypertension and cardiac hypertrophy. 
    Wang X, Chow FL, Oka T, Hao L, Lopez-Campistrous A, Kelly S, Cooper S, Odenbach J, Finegan BA, Schulz R, Kassiri Z, Lopaschuk GD, Fernandez-Patron C.
    Circulation. 2009;119:2480-2489.


  5. Metalloproteinases in hypertension and cardiac disease: Differential expression and mutual regulation. 
    Bosonea AM, Wang X, Odenbach J, Fernandez-Patron C.
    Drug Discov Today Dis Models. (2011) 8:29-35.


  6. Gpcrs in cardiovascular pathologies. 
    Fernandez-Patron C, Filep JG.
    Drug Discov Today Dis Mech. (2012) 9:e75-e78.


  7. Metalloproteinases: Key and common mediators of multiple gpcrs and candidate therapeutic targets in models of hypertensive cardiac disease. 
    Wang X, Bosonea AM, Fernandez-Patron C.
    Drug Discov Today Dis Models. 2012;9:e103-e108. 


  8. Identification of a novel heart/liver axis: Matrix metalloproteinases-2 negatively regulates cardiac secreted phospholipase a2 to modulate lipid metabolism and inflammation in the liver. 
    Hernandez-Anzaldo S, Berry E, Brglez V, Leung D, Yun TJ, Lee JS, Filep JG, Kassiri Z, Cheong C, Lambeau G, Lehner R, Fernandez-Patron C
    J Am Heart Assoc. (2015) Nov 13;4(11).